Navigation Links
Lilly Reports First-Quarter 2013 Results
Date:4/24/2013

, Strattera, Forteo, Alimta, Cymbalta outside the U.S., Effient, Tradjenta® and Axiron®, as well as animal health products. In addition, significant revenue growth is expected in the emerging markets, particularly China, while a continued weakening of the yen could dampen revenue growth in Japan.

The company still anticipates that gross margin as a percent of revenue will be approximately 78 percent.

Marketing, selling and administrative expenses are still expected in the range of $7.1 billion to $7.4 billion. Research and development expenses are now expected to be in the range of $5.3 billion to $5.6 billion.

On a reported basis, other income and deductions is now expected to be in a range between $440 million and $590 million of income in 2013. On a non-GAAP basis, other income and deductions is now expected to be in a range between $50 million of expense to $100 million of income, which excludes $495.4 million of exenatide-related income recognized upon the transfer of exenatide commercial rights outside the U.S. to Amylin.

On a reported basis, the 2013 tax rate is now expected to be approximately 20.5 percent. On a non-GAAP basis, the 2013 tax rate is now expected to be approximately 19.0 percent. Both tax rates for 2013 include the one-time impact associated with the R&D tax credit for 2012 that was recorded in 2013 resulting from the delay in the enactment of the American Taxpayer Relief Act of 2012.

Operating cash flows are still expected to be more than sufficient to allow for capital expenditures of approximately $900 million, fund potential business development activity and pay the company's dividend. In addition, the company has completed its previously-announced $1.5 billion share repurchase program.

Webcast of Conference Call
As previously announced, investors and the general public can access a live webcast of the first-quarter 2013 financial results conference call throu
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. DiversityInc Names Lilly a Top Company for Diversity
2. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
3. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
4. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
5. Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
6. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
7. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
8. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
9. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
10. Lilly Diabetes Launches 8th Annual Diabetes Summer Camp Tour With Olympian Kris Freeman
11. Lilly Declares Third-Quarter 2012 Dividend, Resumes Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  RESMED INC. (NYSE: RMD ) ... fiscal year ended June 30, 2014 results on Thursday, July ... A press release with ResMed,s results will be issued after ... a webcast to discuss operating results and future outlook. ... p.m. US Pacific Time and the live webcast of the ...
(Date:7/10/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... completed the sale to Galderma of all rights to ... by Valeant for $1.4 billion in cash, pursuant to ... completed its acquisition of Galderma. "We ... to a company that is firmly committed to the ...
(Date:7/10/2014)... Israel , July 10, 2014   ... Diabetes Management Solution, today announced the appointment of ... independent member of its Board of Directors. ... legal and business experience to LabStyle as an ... and legal and corporate governance expert. He currently ...
Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4
... Valeritas, Inc., a medical technology ... innovative drug delivery solutions, announced today that the ... company,s V-Go Disposable Insulin Delivery Device for use ... delivery of insulin in preset basal rates and ...
... Dehaier Medical Systems Ltd. (Nasdaq: DHRM ... in the development, assembly, marketing and sale of ... today announced that management will present at the ... (Logo: http://photos.prnewswire.com/prnh/20100422/CNTH001LOGO ) Rodman & ...
Cached Medicine Technology:Valeritas Receives FDA 510(k) Clearance for the V-Go™ Disposable Insulin Delivery Device for Use with NovoLog® 2Valeritas Receives FDA 510(k) Clearance for the V-Go™ Disposable Insulin Delivery Device for Use with NovoLog® 3Dehaier Medical Announces March Investor Presentations 2
(Date:7/12/2014)... July 12, 2014 The report, "Phthalic ... Resins) Market by Application & Geography – Trends & ... with analysis and forecasting of market volume and value. ... the derivatives separately. The market of phthalic anhydride is ... 2013 to $8,415.89 million by 2018, with a CAGR ...
(Date:7/12/2014)... In this cognitive assessment ... and training’ is defined as solution that ... enhance cognitive functions. These solutions are applied ... screening, clinical trials, driver’s safety, rehabilitation, academic ... brain training, and employers’ assessment and training ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 The fastest-growing ... for test and measurement of LTE networks continues to ... demands for smart devices have increased mobile data traffic, ... and Measurement (CT&M) market. Communications Test and Measurement equipment ... requirements. , The Communications Test and Measurement Market is ...
(Date:7/12/2014)... -- If you make exercise fun, you,ll eat less after ... adults were led on a 1.4-mile walk and were either ... walk. The participants were given lunch after the walk, and ... 35 percent more chocolate pudding for dessert than those who ... experiment, 46 adults were given mid-afternoon snacks after their walk. ...
(Date:7/12/2014)... Sean Francis, owner of the Kawartha Lakes Fit Body Boot Camp, ... also known for his support of local non-profits like the Boys ... two and is excited to announce that his fitness boot ... , The funds are the result of Francis’ 21-Day Tummy Tuck ... emails and asked his clients to put out the word that ...
Breaking Medicine News(10 mins):Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 5Health News:Make Exercise Fun, Eat Less Afterwards 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 3
... 10 Enstar Group,Limited ("Enstar") (Nasdaq: ... Enstar Australia Holdings Pty Limited, had entered ... AMP Limited ("AMP") of AMP,s,Australian-based closed reinsurance ... of AUS$585 million (approximately US$518 million)., ...
... it may cause the effect through cerebrovascular disease , ... may be associated with increased risk for mild cognitive ... University Medical Center in New York City. , Mild ... "attracted increasing interest during the past years, particularly as ...
... People rate their smiles higher than dentists do, according ... most important features of an attractive face, the study also ... with their smiles., The study, published in this months Journal ... Norway to rate their own smiles on a 100-point satisfaction ...
... Scheduled for 4:00 p.m. Eastern Time to Review Clinical, Trial ... ... the ASH Meeting, ATLANTA, Dec. 10 ... developing,novel anticancer therapeutics, presented positive results for SNS-595 in,relapsed or refractory ...
... of MGCD0103 Determined as 90 mg, * 53% of Patients ... Responses Experienced a 66% Reduction in the Risk of Death ... Compared to Non-responders, ... (TSX: MYG) today announced maturing data,from the Phase 1/2 study investigating the ...
... 10 Winners of the 2007,Award for Excellence in Human ... and Founder of the Health Improvement,Institute., Winners were: ... Online Clinical Trials Principal Investigator Self ... to educate the University,s researchers on the mechanisms by ...
Cached Medicine News:Health News:Enstar Group Limited Announces Acquisition 2Health News:Hypertension Linked to Risk of Mild Cognitive Impairment 2Health News:Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology 2Health News:Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology 3Health News:Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology 4Health News:Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology 5Health News:Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology 6Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 2Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 3Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 4Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 5Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 6Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 7Health News:2007 Human Research Protection Award Recipients Announced 2
Enhanced drug and formulary reference with integrated ID treatment guide and tools. Increase patient safety and satisfaction with our premium drug reference....
... Eppendorf Reference Series 2000 Pipette is a ... a compact and robust design, and superior ... used to operate the measuring stroke and ... Product features:Eppendorf "pipette/tip" system ensures utmost accuracy ...
... technology that makes fully integrated communication ... a reality. This advance in communication, ... levels means a significantly improved ... stays and improved outcomes. And its ...
The SJM Tailor annuloplasty ring, a fully flexible ring, is constructed of a barium-impregnated silicone strip covered with a knitted polyester sewing cuff....
Medicine Products: